Patients diagnosed with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) have limited options. Research for this condition is vital. INCAGN 2385-203 is a clinical study now enrolling adults with R/M SCCHN.
- It is estimated that a large majority of patients with R/M SCCHN have either no response to standard-of-care treatment or have a response followed by disease progression.1
- Additional immune checkpoints beyond PD-1, including LAG-3 and TIM-3, may play a role in immune suppression and poor disease outcomes in R/M SCCHN.2,3
INCAGN 2385-203 is examining the efficacy and safety of an investigational combination of retifanlimab (anti-PD-1) plus INCAGN02385 (anti-LAG-3) with or without INCAGN02390 (anti-TIM-3) compared to retifanlimab alone. For more information on this clinical study, please visit Incyte Clinical Trials [incyteclinicaltrials.com].
- Chow LQM. Head and neck cancer. N Engl J Med 2020;382:60-72.
- Jie HB, Gildener-Leapman N, Li J, et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 2013;109:2629-2635.
- Shayan G, Srivastava R, Li J, Schmitt N, Kane LP, Ferris RL. Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. Oncoimmunology 2016;6:e1261779.